NCT05930457 is a Phase 1 clinical trial of 2.5-3.5mCi 64Cu-FAPI-XT117 in Malignant Solid Tumors, sponsored by The First Affiliated Hospital of Guangzhou Medical University.

Who is sponsoring NCT05930457?

NCT05930457 is sponsored by The First Affiliated Hospital of Guangzhou Medical University.

What drugs are being tested in NCT05930457?

Interventions in NCT05930457: 2.5-3.5mCi 64Cu-FAPI-XT117, 3.5-4.5mCi 64Cu-FAPI-XT117, 4.5-5.5mCi 64Cu-FAPI-XT117.

What condition does NCT05930457 study?

NCT05930457 studies Malignant Solid Tumors.

Is NCT05930457 still recruiting?

NCT05930457 is currently completed. Last updated 26 December 2023.

Last reviewed 2023-12-26 · How we verify

NCT05930457

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

Completed Phase 1 Last updated 26 December 2023

What this trial tests

Phase 1 trial testing 2.5-3.5mCi 64Cu-FAPI-XT117 in Malignant Solid Tumors in 15 participants. Completed in 18 December 2023.

Timeline

26 July 2023

Primary endpoint
31 October 2023

18 December 2023

Quick facts

Lead sponsor	The First Affiliated Hospital of Guangzhou Medical University
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	15
Start date	26 July 2023
Primary completion	31 October 2023
Estimated completion	18 December 2023
Sites	1 location across China

Drugs / interventions tested

2.5-3.5mCi 64Cu-FAPI-XT117 — full drug profile →
3.5-4.5mCi 64Cu-FAPI-XT117 — full drug profile →
4.5-5.5mCi 64Cu-FAPI-XT117 — full drug profile →

Conditions studied

Malignant Solid Tumors — all drugs for Malignant Solid Tumors →

Sponsor

The First Affiliated Hospital of Guangzhou Medical University

Who can join

18 and older, any sex, with Malignant Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is the study of 64Cu-FAPI-XT117, which is an prospective, single-arm phase I clinical study.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

<i>CopperNostics</i>-Here We Are Now, Entertain Us!
Brühlmann SA, Walther M, Kopka K, Kreller M, et al · · 2026 · PMID 41754861 · DOI 10.3390/ph19020321
Safety and efficacy of <sup>177</sup>Lu-FAPI-XT radioligand therapy in patients with advanced sarcoma and other cancer entities: first-in-human, dose-escalation study.
Liu H, Guo R, Zhang X, Ji H, et al · · 2026 · PMID 41087606 · DOI 10.1007/s00259-025-07617-0

Verify or expand the search:

Other recruiting trials for Malignant Solid Tumors

Currently open trials in the same condition.

NCT06629584 — Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia · Phase 2 · recruiting
NCT06702566 — The Effect of Serum Ferritin in irAE · NA · recruiting
NCT05579275 — Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant · EARLY_PHASE1 · recruiting
NCT03739827 — Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors · recruiting

Other The First Affiliated Hospital of Guangzhou Medical University trials

Trials by the same sponsor.

NCT07413952 — Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases · Phase 2 · not yet recruiting
NCT07395375 — Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection · NA · not yet recruiting
NCT07395362 — Hybrid Robot-Assisted Percutaneous Ablation and Non-Intubated VATS for Multiple Pulmonary Nodules · NA · not yet recruiting
NCT07395349 — Safety And Recovery Of Tubeless Strategy In Uniportal VATS Wedge Resection · NA · not yet recruiting
NCT07377916 — Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05930457 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Guangzhou Medical University
Last refreshed: 26 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05930457.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing